Distinguished in Non-Hodgkin Lymphoma

Dr. Ronald S. Levy

Oncology | Hematology Oncology | Hematology
300 Pasteur Dr, 
Stanford, CA 
Distinguished in Non-Hodgkin Lymphoma
300 Pasteur Dr, 
Stanford, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ronald Levy is an Oncologist and a Hematologist Oncology provider in Stanford, California. Dr. Levy is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), and B-Cell Lymphoma.

His clinical research consists of co-authoring 102 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 43 articles and participated in 4 clinical trials in the study of Non-Hodgkin Lymphoma.

Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO

Locations

300 Pasteur Dr, Stanford, CA 94305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With BMS-986178 and Local Radiation in Low-Grade B-Cell Lymphomas
Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With BMS-986178 and Local Radiation in Low-Grade B-Cell Lymphomas
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Drug, Biological, Other, Radiation
Study Drugs: Anti-OX40 Antibody BMS 986178, TLR9 Agonist SD-101
Study Phase: Phase 1
Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular Lymphoma
Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular Lymphoma
Enrollment Status: Completed
Publish Date: October 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: Ibrutinib, TLR9 Agonist SD-101
Study Phase: Phase 1/Phase 2
The Seena Magowitz Phase IB/II Trial of CMP-001 (a TLR9 Agonist) in Combination With INCAGN01949 (an Activating Anti-OX40 Antibody) for In Situ Intratumoral Injection for Patients With Stage IV Pancreatic and Other Cancers Except Melanoma
The Seena Magowitz Phase IB/II Trial of CMP-001 (a TLR9 Agonist) in Combination With INCAGN01949 (an Activating Anti-OX40 Antibody) for In Situ Intratumoral Injection for Patients With Stage IV Pancreatic and Other Cancers Except Melanoma
Enrollment Status: Terminated
Publish Date: March 22, 2023
Intervention Type: Biological, Drug
Study Drugs: Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001
Study Phase: Phase 1/Phase 2
Phase 1-2 Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for Mantle Cell Lymphoma
Phase 1-2 Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: January 13, 2020
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Phase I/II Study of Intratumoral Injection of SD-101, an Immunostimulatory CpG, and Intratumoral Injection of Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Combination With Local Radiation in Low-Grade B-Cell Lymphomas
A Phase I/II Study of Intratumoral Injection of SD-101, an Immunostimulatory CpG, and Intratumoral Injection of Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Combination With Local Radiation in Low-Grade B-Cell Lymphomas
Enrollment Status: Completed
Publish Date: November 27, 2019
Intervention Type: Biological, Radiation, Drug
Study Phase: Phase 1/Phase 2
A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas
A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas
Enrollment Status: Terminated
Publish Date: September 25, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

102 Total Publications

Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging.
Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 10, 2025
Similar Doctors
Ranjana H. Advani
Elite in Non-Hodgkin Lymphoma
Dr. Ranjana H. Advani
Oncology | Hematology
Elite in Non-Hodgkin Lymphoma
Dr. Ranjana H. Advani
Oncology | Hematology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ranjana Advani is an Oncologist and a Hematologist in Stanford, California. Dr. Advani has been practicing medicine for over 43 years and is rated as an Elite provider by MediFind in the treatment of Non-Hodgkin Lymphoma. Her top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy.

Elite in Non-Hodgkin Lymphoma
Dr. David B. Miklos
Hematology | Hematology Oncology | Oncology
Elite in Non-Hodgkin Lymphoma
Dr. David B. Miklos
Hematology | Hematology Oncology | Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Miklos is a Hematologist and a Hematologist Oncology provider in Stanford, California. Dr. Miklos is rated as an Elite provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), B-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Elite in Non-Hodgkin Lymphoma
Dr. Michael S. Khodadoust
Oncology | Hematology | Hematology Oncology
Elite in Non-Hodgkin Lymphoma
Dr. Michael S. Khodadoust
Oncology | Hematology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Khodadoust is an Oncologist and a Hematologist in Stanford, California. Dr. Khodadoust is rated as an Elite provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are T-Cell Lymphoma, Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Levy's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile